TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6666232
Drug: ASA (before
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA (before ISDN administration)
Study: 28866447
Drug: Verum tDCS
Normalized name: Cinnamomum verum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verum tDCS (2-mA, twice-daily sessions for 5-days)
Study: 22563194
Drug: LCR35 (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCR35 (n = 25) at a minimum daily dose of 6 × 10(8) colony forming units for 4 weeks
Study: 17661765
Drug: Oral chili
Normalized name: Chili oleoresin
DrugBank: Capsicum oleoresin (DB11131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chili (5 g daily x 3 days)
Study: 17661765
Drug: Oral chili
Normalized name: Chili oleoresin
DrugBank: Capsicum oleoresin (DB11131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chili with 1-mg intravenous granisetron
Study: 17661765
Drug: Intravenous granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous granisetron after placebo ingestion
Study: 16310024
Drug: Psychological stressor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological stressor (administered to 21 patients during the last 90 min of 24-h oesophageal pH monitoring)
Study: 16310024
Drug: No-stress control
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-stress control condition (administered to the remaining participants)
Study: 10203878
Drug: 25% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% of the 4-hourly opioid dose
Study: 10203878
Drug: 50% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% of the 4-hourly opioid dose
Study: 7780069
Drug: Meperidine, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine, 25 to 75 mg (n = 10)
Study: 7780069
Drug: Vecuronium, 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium, 0.1 microgram/kg (n = 10), continued as an infusion at 1.0 microgram/kg/min for 4 hours
Study: 393465
Drug: Protacine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protacine (150 mg, 3 times daily for 21 days)
Study: 393465
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg, 3 times daily for 21 days)
Study: 30649375
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose (twice the maintenance dose)
Study: 14979213
Drug: Keyouling oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keyouling oral liquid (high-dosage group)
Study: 14979213
Drug: Keyouling oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keyouling oral liquid (treatment group)
Study: 11305831
Drug: 0.15 mg
Normalized name: iodine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg clonidine (Group-CL, n=20)
Study: 11305831
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg diazepam (Group-DZ, n=20)
Study: 9220179
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine (2 micrograms/kg/min)
Study: 9220179
Drug: Intravenous bumetanide
Normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous bumetanide (1 mg b.i.d.) alone
Study: 11767421
Drug: Netilmicin 2
Normalized name: netilmicin 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netilmicin 2 mg kg‐1
Study: 11767421
Drug: Cefuroxime 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 20 mg kg‐1
Study: 11767421
Drug: Metronidazole 7.5
Normalized name: metronidazole 7.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 7.5 mg kg‐1
Study: 11767421
Drug: Cefuroxime 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 20 mg kg‐1 and Metronidazole 7.5 mg kg‐1
Study: 29570588
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of parenteral nutrition
Study: 25768376
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg/kg for intubation followed by sugammadex 4.0 mg/kg for reversal.
Study: 25768376
Drug: Succinylcholine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 1.0 mg/kg for intubation with spontaneous recovery.
Study: 22672501
Drug: vildagliptin/metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: vildagliptin/metformin
Study: 22672501
Drug: metformin only
Normalized name: Metformin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin only
Study: 17121765
Drug: Bromelain 800
Normalized name: Bromelain
DrugBank: Bromelains (DB13281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromelain 800 mg/day
Study: 12933427
Drug: Remifentanil 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.75 micro g/kg in bolus, followed by continuous infusion of 0.075 micro g x kg(‐1) x min(‐1) (Group L)
Study: 12933427
Drug: Remifentanil 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1.5 micro g/kg in bolus, followed by continuous infusion of 0.15 micro g x kg(‐1) x min(‐1) (Group H)
Study: 11529283
Drug: Formoterol (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (twice daily 24 microg by Turbuhaler)
Study: 11529283
Drug: Salmeterol (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (twice daily 100 microg by Diskhaler)
Study: 8220396
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid (protein) capsules
Study: 8220396
Drug: Lactose (placebo)
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose (placebo) capsules
Study: 3327931
Drug: Hydrochlorothiazide (HCTZ,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ, 12.5 mg twice daily)
Study: 31389672
Drug: 0.02% PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02% PCA lotion for 8 weeks
Study: 30606315
Drug: Universal isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Universal isoniazid preventive therapy (IPT)
Study: 25680623
Drug: 4-drug regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4-drug regimen (irinotecan, oxaliplatin, tegafur-uracil with leucovorin and cetuximab)
Study: 18510819
Drug: Taste-masked quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taste-masked quinine sulphate pellets (600 mg single dose for adults; 10-12.5 mg/kg every 8 hours for 7 days for children)
Study: 18510819
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available tablets (control for adults)
Study: 16918261
Drug: Epratuzumab (humanised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epratuzumab (humanised anti-CD22 antibody)
Study: 8922570
Drug: Erythromycin estolate
Normalized name: Erythromycin Estolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin estolate (40 mg/kg/d in two divided doses for five days)
Study: 8922570
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V (30 mg/kg/d in three divided doses for ten days)
Study: 29390048
Drug: Intermediate-dose cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intermediate-dose cytarabine (1000 mg/m2 twice daily on days 1, 3, 5, 7) plus mitoxantrone (10 mg/m2 days 1-3) (IMA)
Study: 29390048
Drug: Standard induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard induction therapy with cytarabine (100 mg/m2 continuously days 1-7) plus daunorubicin (45 mg/m2 days 3-5) (DA)
Study: 29390048
Drug: Intermediate-dose cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intermediate-dose cytarabine plus mitoxantrone (IMA)
Study: 29390048
Drug: Standard induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard induction therapy with cytarabine plus daunorubicin (DA)
Study: 28453759
Drug: Leukapheresis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukapheresis treatment with CCL25 column
Study: 26222774
Drug: eGFR <60
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR <60 ml/min/1.73 m2 and elevated OPG
Study: 26222774
Drug: eGFR ≥60
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR ≥60 ml/min/1.73 m2 and low OPG
Study: 16507398
Drug: exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: exemestane 25 mg daily and celecoxib 400 mg twice-daily (Group A)
Study: 16507398
Drug: exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: exemestane 25 mg daily (Group B)
Study: 16507398
Drug: letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: letrozole 2.5 mg daily (Group C)
Study: 12090818
Drug: Desipramine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (mean total daily dose, 3.4 mg/kg per day)
Study: 10613165
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical nerve stimulation as analgesic and exercise
Study: 25392341
Drug: Dexmedetomidine 4
Normalized name: DEXMEDETOMIDINE 4MCG/ML/NS INJ BAG 50ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 4 µg/cc
Study: 25392341
Drug: Dexmedetomidine 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 8 µg/cc
Study: 24811963
Drug: Aganirsen eye
Normalized name: Aganirsen
DrugBank: Aganirsen (DB15369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aganirsen eye drops (86 μg/day/eye) applied twice daily for 90 days
Study: 19151567
Drug: 5'‐DFUR for
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5'‐DFUR for postoperative 10 months (1,200 mg/body/day for five days followed by two days rest)
Study: 2448145
Drug: Combination doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination doxorubicin and mitomycin C (DM)
Study: 2448145
Drug: Combination cisplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination cisplatin, vinblastine and bleomycin (PVB)
Study: 30943497
Drug: Bromazepam 3
Normalized name: bromazepam 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam 3 mg plus Propranolol 40 mg
Study: 29208690
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogen (0.45 mg/day), n=18
Study: 29208690
Drug: Transdermal 17β-estradiol
Normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal 17β-estradiol (50 μg/day) with oral micronized progesterone (Prometrium 200 mg), n=23
Study: 29208690
Drug: Placebo pills
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills and patch, n=26
Study: 25488344
Drug: DC group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: DC group (double-coated probiotic formulation)
Study: 25488344
Drug: NC group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: NC group (non-coated probiotic formulation)
Study: 21507257
Drug: Structured interview
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured interview followed by visits every 2-3 weeks to the end of dose reduction
Study: 21507257
Drug: Structured interview
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured interview plus delivery of written instructions to self-reduce benzodiazepine dose
Study: 18713842
Drug: Metyrapone (METY,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metyrapone (METY, 3 g)
Study: 18713842
Drug: Ketoconazole (KTCZ,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (KTCZ, 1.2 g)
Study: 12816022
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care (including medical record review, medication history review, pharmacotherapeutic evaluation, patient medication education and monitoring over one year)
Study: 9199125
Drug: Theophylline (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (3.5 mg/kg) administered intravenously to humans with mixed-form hyperlipidemia
Study: 9199125
Drug: Theophylline (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (12 mg/kg) administered intravenously to hyperlipidemic rabbits
Study: 6849784
Drug: Intravenous chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous chloroquine (300 mg)
Study: 6849784
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution chloroquine (300 mg)
Study: 6849784
Drug: Chloroquine tablets
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine tablets (300 mg)
Study: 6849784
Drug: Oral doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doses of chloroquine
Study: 27365077
Drug: Genta‐Coll group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genta‐Coll group (G‐group)
Study: 22586827
Drug: Treatment-control (table
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-control (table stabilization)
Study: 15592329
Drug: Fluconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (200 mg daily) with Dapsone (100 mg daily)
Study: 15592329
Drug: Rifabutin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifabutin (300 mg daily) with Dapsone (100 mg daily)
Study: 15592329
Drug: Fluconazole plus
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole plus Rifabutin with Dapsone (100 mg daily)
Study: 15592329
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg twice daily) with Dapsone (100 mg daily)
Study: 15592329
Drug: Dapsone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone (100 mg daily) alone
Study: 11359439
Drug: HAART (Highly
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART (Highly Active Antiretroviral Therapy) for 12 months
Study: 9644873
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day of ZAM
Study: 3218660
Drug: 1 alpha(OH)D3
Normalized name: 1-alpha-25-Dihydroxyvitamin D3
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 alpha(OH)D3 treatment (2 micrograms for 3 months)
Study: 27785091
Drug: Botulinum toxin‐A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin‐A (BTX‐A) injection
Study: 21346512
Drug: Once-daily DRV/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily DRV/r 800/100 mg
Study: 21346512
Drug: Twice-daily DRV/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily DRV/r 600/100 mg
Study: 10894321
Drug: Enalapril 5-20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5-20 mg od
Study: 10894321
Drug: Nifedipine 30-90
Normalized name: nifedipine 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 30-90 mg od
Study: 7402771
Drug: Oral salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral salbutamol (0.15 mg/kg)
Study: 7402771
Drug: Salbutamol aerosol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol aerosol (0.2 mg)
Study: 30481106
Drug: Commercial scale
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial scale (CS) vaccine lot 1
Study: 30481106
Drug: Commercial scale
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial scale (CS) vaccine lot 2
Study: 30481106
Drug: Commercial scale
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial scale (CS) vaccine lot 3
Study: 30481106
Drug: Licensed pilot
Normalized name: Picot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed pilot scale (LPS) vaccine
Study: 19445861
Drug: Dexamethasone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.5 mg/kg)
Study: 8703690
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (20 Gy in five fractions)
Study: 2127786
Drug: Interferon (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (2 million units, subcutaneous injections three times weekly for 6 months)
Study: 2127786
Drug: Placebo (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (subcutaneous injections three times weekly for 6 months)
Study: 10682943
Drug: Symptom-limited exercise
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom-limited exercise testing for peak oxygen consumption (VO2peak, mL/kg/min)
Study: 8656171
Drug: Erythromycin 250
Normalized name: erythromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 250 mg four times daily for 10 days
Study: 1672176
Drug: ICI 204.219
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 204.219 (40 mg single oral dose)
Study: 6307464
Drug: Intravenous acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acyclovir 5 mg/kg twice daily during granulocytopenia
Study: 31977370
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg chlorzoxazone 3 times daily for the first 7 days postoperatively
Study: 26434934
Drug: AMG 151
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 151 (50, 100, or 200mg twice daily)
Study: 26434934
Drug: AMG 151
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 151 (100, 200, or 400mg once daily)
Study: 24225595
Drug: Low-dose whey
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose whey protein isolate (0.8 g·kg1·d1; W1)
Study: 24225595
Drug: High-dose whey
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose whey protein isolate (1.6 g·kg1·d1; W2)
Study: 22423128
Drug: Linezolid (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (exact dosage and duration not specified)
Study: 15058116
Drug: Lignocaine with
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine with 5 ml saline (Control Group L)
Study: 11407430
Drug: Indirectly related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirectly related words (e.g., sofa) used as primes for low-frequency inconsistent words in naming tasks.
Study: 11407430
Drug: Indirectly related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirectly related words (e.g., sofa) used as primes for high-frequency inconsistent words in a speeded naming task.
Study: 3306500
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered cefuroxime and metronidazole (three-dose perioperative course)
Study: 29371115
Drug: Sedation administered
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation administered in treatment groups
Study: 23394782
Drug: Controlled ovarian
Normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled ovarian stimulation with highly purified human menopausal gonadotropin (hphMG) or recombinant FSH in a GnRH antagonist cycle.
Study: 7628032
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine (5 micrograms.kg-1)
Study: 1974498
Drug: S(−)‐CARV after
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(−)‐CARV after i.v. administration
Study: 1974498
Drug: R(+)‐CARV after
Approvals — FDA: no, EMA: no, PMDA: no
Description: R(+)‐CARV after i.v. administration
Study: 1974498
Drug: S(−)‐CARV after
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(−)‐CARV after p.o. administration
Study: 1974498
Drug: R(+)‐CARV after
Approvals — FDA: no, EMA: no, PMDA: no
Description: R(+)‐CARV after p.o. administration
Study: 31174586
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) followed by rituximab
Study: 31174586
Drug: Placebo infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusions of 1% albumin followed by 0.9% sodium chloride
Study: 27085996
Drug: EPA +
Normalized name: Eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPA + DHA supplementation (600 mg EPA and 260 mg DHA per day)
Study: 24775812
Drug: Ciprofloxacin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (10 doses of 500 mg every 12 hours during 5 days)
Study: 24775812
Drug: Fosfomycin-trometamol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin-trometamol (2 doses of 3g every 48 hours)
Study: 18363884
Drug: GH-treatment (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH-treatment (1 mg/m²/day) in infants (n=20) for 1 year
Study: 18363884
Drug: GH-treatment (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH-treatment (1 mg/m²/day) in children > 3 years (n=27) for 2 years
Study: 18363884
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment) in infants (n=22) for 1 year
Study: 18363884
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment) in children > 3 years (n=22) for 2 years
Study: 18363884
Drug: GH-treatment (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH-treatment (1 mg/m²/day) in infants and children
Study: 18363884
Drug: GH-treatment (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH-treatment (1 mg/m²/day) in children
Study: 15957834
Drug: Sodium ferulate
Normalized name: ferulate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium ferulate (SF) treatment for 4 weeks
Study: 7703389
Drug: L-Arginine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Arginine (5 mg/kg per minute for 90 min)
Study: 7703389
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of endothelin and L-arginine
Study: 373560
Drug: Administration sets
Normalized name: administration sets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration sets changed every 24 hours